Bristol-Myers: "Boring Is Good"
May 09, 2022 at 10:54 AM EDT
The firm’s big money-making drug, Revlimid (acquired when it bought Celgene a few years back), which treats a cancer of plasma cells called multiple myeloma, is facing increasing generic competition.